Benzinga | Aug 10, 2020 07:09AM EDT

Intercept Pharmaceuticals Q2 EPS $(1.92) Beats $(2.92) Estimate, Sales $77.25M Beat $72.15M Estimate

Intercept Pharmaceuticals (NASDAQ:ICPT) reported quarterly losses of $(1.92) per share which beat the analyst consensus estimate of $(2.92) by 34.25 percent. This is a 15.79 percent increase over losses of $(2.28) per share from the same period last year. The company reported quarterly sales of $77.25 million which beat the analyst consensus estimate of $72.15 million by 7.07 percent. This is a 16.51 percent increase over sales of $66.30 million the same period last year.